The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

May 30, 2024

Study Completion Date

November 1, 2024

Conditions
Fecal Incontinence
Interventions
DRUG

Ramosetron

Ramosetron (a 5-HT3 receptor antagonist) has been developed as an effective treatment for irritable bowel syndrome-diarrhea (IBD-D) and is used to decrease intestinal motility, stiffen stool consistency, and reduce the number of urgency bowel movements. Since one of the goals of treatment for fecal incontinence is the maintenance of stool consistency, this agent is expected to be effective in treating fecal incontinence.

DRUG

Psyllium

Psyllium was found to be the most effective at improving symptoms of fecal incontinence among several dietary fibers in a randomized, controlled, single-blind study and is currently used as a first-line treatment for fecal incontinence.

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT06166615 - The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence | Biotech Hunter | Biotech Hunter